PRKDC and neuroblastoma: Regarding concomitant treatment with targeted drugs and CHK1 inhibitors, we previously demonstrated that an inhibitor of ATM or DNA-dependent protein kinase (DNA-PK) potentiates CHK1 inhibitor-mediated growth suppression in MYCN-amplified neuroblastoma cell lines [86].